Top

Published in:

01-08-2014 | Research Article

Generation of a monoclonal antibody specific to a new candidate tumor suppressor, cell adhesion molecule 2

Authors: Meijin Huang, Ziyuan Xia, Yang Wang, Liang Huang, Qian Ma, Xia Chen, Hao Wang, Bin Lu, Yajun Guo

Published in: Tumor Biology | Issue 8/2014

Abstract

Cell adhesion molecule 2 (CADM2) is an immunoglobulin (Ig)-like cell adhesion molecule, which belongs to the CADMs family. The four members of CADMs family including three Ig-like domains and a short cytoplasmic tail share high degree of identity with each other, making it difficult to specifically identify each members using western blotting or immunohistochemistry. And most of anti-CADM2 antibodies available commercially or used in published papers are rabbit polyclonal antibodies, exhibiting nonspecific recognition in studies. In this study, we developed a monoclonal antibody (mAb) specific to an epitope on the extracellular domain of CADM2 using conventional hybridoma technology. Western blot assays indicated that the established mAb, named as 2B11, was specific for CADM2 recognition without interference of other members of CADMs family. Furthermore, 2B11 was competent to detect CADM2 expression specifically on the surface membranes of several types of tumor tissues, avoiding the false results with the polyclonal antibodies due to nonspecific staining. In conclusion, the mAb 2B11 could be suitable for specific detection of CADM2 expression in tumor cells or tissues.

Cavenee WK, White RL. The genetic basis of cancer. Sci Am. 1995;272(3):72–9.PubMedCrossRef

Murakami Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci. 2005;96(9):543–52.PubMedCrossRef

Raveh S et al. The cell adhesion nectin-like molecules (Necl) 1 and 4 suppress the growth and tumorigenic ability of colon cancer cells. J Cell Biochem. 2009;108(1):326–36.PubMedCrossRef

Kikuchi S et al. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma. Cancer. 2006;106(8):1751–8.PubMedCrossRef

Heller G et al. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene. 2006;25(6):959–68.PubMedCrossRef

Gao J et al. Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. Glia. 2009;57(9):989–99.PubMedCrossRef

Fukuhara H et al. Isolation of the TSLL1 and TSLL2 genes, members of the tumor suppressor TSLC1 gene family encoding transmembrane proteins. Oncogene. 2001;20(38):5401–7.PubMedCrossRef

Morrissey C et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001;61(19):7277–81.PubMed

Martinez A et al. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol. 2000;53(3):137–44.PubMedCentralPubMedCrossRef

10.

Lo KW et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001;61(10):3877–81.PubMed

11.

Berger MF et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470(7333):214–20.PubMedCentralPubMedCrossRef

12.

Chow LS et al. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer. 2004;109(6):839–47.PubMedCrossRef

13.

Chang G et al. Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. Clin Cancer Res. 2010;16(22):5390–401.PubMedCentralPubMedCrossRef

14.

He W et al. Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. Biochem Biophys Res Commun. 2013;435(4):526–32.PubMedCrossRef

15.

Biederer T et al. SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science. 2002;297(5586):1525–31.PubMedCrossRef

16.

Biederer T. Bioinformatic characterization of the SynCAM family of immunoglobulin-like domain-containing adhesion molecules. Genomics. 2006;87(1):139–50.PubMedCrossRef

17.

Fogel AI et al. SynCAMs organize synapses through heterophilic adhesion. J Neurosci. 2007;27(46):12516–30.PubMedCrossRef

18.

Gao J et al. Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity. Biochim Biophys Acta. 2008;1778(6):1429–35.PubMedCrossRef

19.

Fogel AI et al. N-glycosylation at the SynCAM (synaptic cell adhesion molecule) immunoglobulin interface modulates synaptic adhesion. J Biol Chem. 2010;285(45):34864–74.PubMedCentralPubMedCrossRef

20.

Overmeer RM et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol. 2008;215(4):388–97.PubMedCrossRef

21.

Shen YD et al. Development of a monoclonal antibody-based competitive indirect enzyme-linked immunosorbent assay for furaltadone metabolite AMOZ in fish and shrimp samples. J Agric Food Chem. 2012;60(44):10991–7.PubMedCrossRef

22.

Deng YQ et al. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One. 2011;6(1):e16059.PubMedCentralPubMedCrossRef

23.

Zhao J. L.B., Xu H, Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma. Hepatology. 2008;48:265–75.PubMedCrossRef

24.

Lu B et al. Increased expression of iASPP, regulated by hepatitis B virus X protein-mediated NF-kappaB activation, in hepatocellular carcinoma. Gastroenterology. 2010;139(6):2183–2194 e5.PubMedCrossRef

Title: Generation of a monoclonal antibody specific to a new candidate tumor suppressor, cell adhesion molecule 2
Authors: Meijin Huang
Ziyuan Xia
Yang Wang
Liang Huang
Qian Ma
Xia Chen
Hao Wang
Bin Lu
Yajun Guo
Publication date: 01-08-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 8/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1980-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2014

Inhibition of macrophage polarization prohibits growth of human osteosarcoma

The specific methylation characteristics of cancer related genes in Chinese colorectal cancer patients

Midazolam inhibits the proliferation of human head and neck squamous carcinoma cells by downregulating p300 expression

ncRuPAR inhibits gastric cancer progression by down-regulating protease-activated receptor-1

Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status

Decreased ARID1A expression facilitates cell proliferation and inhibits 5-fluorouracil-induced apoptosis in colorectal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer